[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA202091888A1 - Вариабельные домены антител, нацеленные на рецептор nkg2d - Google Patents

Вариабельные домены антител, нацеленные на рецептор nkg2d

Info

Publication number
EA202091888A1
EA202091888A1 EA202091888A EA202091888A EA202091888A1 EA 202091888 A1 EA202091888 A1 EA 202091888A1 EA 202091888 A EA202091888 A EA 202091888A EA 202091888 A EA202091888 A EA 202091888A EA 202091888 A1 EA202091888 A1 EA 202091888A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nkg2d receptor
antibody domains
variable antibody
nkg2d
domains targeted
Prior art date
Application number
EA202091888A
Other languages
English (en)
Inventor
Грегори П. Чан
Энн Ф. Чеунг
Ася ГРИНБЕРГ
Уилльям Хани
Брэдли М. Лунде
Бьянка Принц
Original Assignee
Драгонфлай Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Драгонфлай Терапьютикс, Инк. filed Critical Драгонфлай Терапьютикс, Инк.
Priority claimed from PCT/US2019/017330 external-priority patent/WO2019157366A1/en
Publication of EA202091888A1 publication Critical patent/EA202091888A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Описаны вариабельные домены тяжелой цепи антитела, которые могут быть спарены с вариабельными доменами легкой цепи антитела с образованием антигенсвязывающего участка, нацеленного на рецептор NKG2D на поверхности естественных клеток-киллеров. Также описаны белки, содержащие участок, связывающий антиген NKG2D, фармацевтические композиции, содержащие их, и способы лечения, в том числе лечения рака.
EA202091888A 2018-08-08 2019-02-08 Вариабельные домены антител, нацеленные на рецептор nkg2d EA202091888A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862716259P 2018-08-08 2018-08-08
PCT/US2019/017330 WO2019157366A1 (en) 2018-02-08 2019-02-08 Antibody variable domains targeting the nkg2d receptor

Publications (1)

Publication Number Publication Date
EA202091888A1 true EA202091888A1 (ru) 2020-10-23

Family

ID=69413631

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091888A EA202091888A1 (ru) 2018-08-08 2019-02-08 Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202190453A EA202190453A1 (ru) 2018-08-08 2019-08-07 Полиспецифические связывающие белки, которые связываются с her2, nkg2d и cd16, и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202190453A EA202190453A1 (ru) 2018-08-08 2019-08-07 Полиспецифические связывающие белки, которые связываются с her2, nkg2d и cd16, и способы их применения

Country Status (18)

Country Link
US (1) US20210198369A1 (ru)
EP (2) EP4249067A3 (ru)
JP (1) JP7431394B2 (ru)
KR (1) KR102645411B1 (ru)
CN (1) CN112770769B (ru)
AU (1) AU2019318425B2 (ru)
BR (1) BR112021002213A2 (ru)
CA (1) CA3108794A1 (ru)
DK (1) DK3833386T5 (ru)
EA (2) EA202091888A1 (ru)
ES (1) ES2954851T3 (ru)
FI (1) FI3833386T3 (ru)
IL (1) IL280656B2 (ru)
MX (1) MX2021001508A (ru)
SA (1) SA521421188B1 (ru)
SG (1) SG11202101276QA (ru)
WO (1) WO2020033587A1 (ru)
ZA (1) ZA202100916B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
PE20221404A1 (es) * 2019-08-30 2022-09-15 Dragonfly Therapeutics Inc Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer
EP4146695A1 (en) * 2020-05-04 2023-03-15 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
CN116023501A (zh) * 2021-10-25 2023-04-28 三生国健药业（上海）股份有限公司 一种抗her2的免疫毒素分子、及其制备方法与应用
WO2024081329A1 (en) * 2022-10-12 2024-04-18 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101299599B1 (ko) * 2003-07-24 2013-08-23 위니베르시따 데글리 스뚜디 디 뻬루지아 Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을 높이는 방법 및 조성물
JP2009500346A (ja) 2005-06-29 2009-01-08 ユニバーシティー・オブ・マイアミ 癌処置用の抗体−免疫細胞リガンド融合タンパク質
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2714738B1 (en) * 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US9610332B2 (en) * 2012-07-18 2017-04-04 Massachusetts Institute Of Technology Compositions and methods for modulating BRD4 bioactivity
US9562110B2 (en) 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
ES2861446T3 (es) 2012-11-27 2021-10-06 Univ Ajou Ind Academic Coop Found Par de variantes del dominio CH3 que induce la formación de heterodímero de la región constante de la cadena pesada del anticuerpo con alta eficiencia, método para prepararlo y uso del mismo
BR112015017560A2 (pt) * 2013-01-24 2018-05-15 Scripps Korea Antibody Institute biblioteca de fv à base de combinação de proteína e modo de preparação da mesma
AU2014232501C1 (en) 2013-03-15 2021-04-22 Xencor, Inc. Heterodimeric proteins
TW201536810A (zh) 2013-07-15 2015-10-01 Novo Nordisk As 結合尿激酶纖維蛋白溶酶原活化物之抗體
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
TW201542594A (zh) * 2014-04-11 2015-11-16 Medimmune Llc 雙特異性ｈｅｒ２抗體
EP4043474A1 (en) * 2014-12-05 2022-08-17 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
US20180318417A1 (en) 2015-01-14 2018-11-08 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
SI3303394T1 (sl) * 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
WO2017079694A2 (en) * 2015-11-04 2017-05-11 Priceman Saul J Chimeric antigen receptors targeting her2
WO2017081190A1 (en) * 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
JP7082604B2 (ja) * 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
JOP20190134A1 (ar) * 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
SG11201907299XA (en) * 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
KR20240060739A (ko) * 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
US11884733B2 (en) * 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения

Also Published As

Publication number Publication date
DK3833386T5 (da) 2024-08-19
IL280656B1 (en) 2023-11-01
ES2954851T3 (es) 2023-11-27
FI3833386T3 (fi) 2023-08-28
JP7431394B2 (ja) 2024-02-15
SA521421188B1 (ar) 2024-07-25
IL280656B2 (en) 2024-03-01
EP4249067A2 (en) 2023-09-27
EP3833386A4 (en) 2022-07-06
CN112770769B (zh) 2024-07-12
ZA202100916B (en) 2024-08-28
WO2020033587A1 (en) 2020-02-13
CA3108794A1 (en) 2020-02-13
IL280656A (en) 2021-03-25
KR20210042121A (ko) 2021-04-16
US20210198369A1 (en) 2021-07-01
EA202190453A1 (ru) 2021-06-10
JP2021533161A (ja) 2021-12-02
MX2021001508A (es) 2021-07-02
DK3833386T3 (da) 2023-09-04
BR112021002213A2 (pt) 2021-07-20
EP3833386A1 (en) 2021-06-16
SG11202101276QA (en) 2021-03-30
EP3833386B1 (en) 2023-06-14
CN112770769A (zh) 2021-05-07
AU2019318425B2 (en) 2024-02-29
EP4249067A3 (en) 2023-11-22
KR102645411B1 (ko) 2024-03-11
AU2019318425A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA202090812A1 (ru) Новые биспецифические полипептидные комплексы
EA202092668A1 (ru) Антитела к ил-11
EA202092605A1 (ru) Антитела к ил-11ra
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
EA201990183A1 (ru) Аденовирус, вооруженный биспецифичным активатором т-клеток (bite)
EA201991729A1 (ru) Антитела к tgf-бета и их применение
EA202192810A1 (ru) АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
EA202190468A1 (ru) Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
MX2022004291A (es) Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos.
MX2022013882A (es) Anticuerpos dirigidos contra el miembro a de la familia de dominios de lectina tipo c 12 (clec12a) y uso de los mismos.
MX2023001556A (es) Anticuerpos que se dirigen a egfr y uso de los mismos.
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
BR112018006820A2 (pt) anticorpos anti-psa (5a10) humanizados
CL2022002569A1 (es) Dominios variables de anticuerpos dirigidos al receptor nkg2d
EA202190071A1 (ru) Антитела к pd-1 и их применение
EA202092279A1 (ru) Антитела к mica и/или micb и их применение
EA201891989A1 (ru) Антитела к tigit